Role of multi-hnRNP nuclear complex in regulation of tumor suppressor ANXA7 in prostate cancer cells

Oncogene

Volumn 29, Issue 17, 2010, Pages 2457-2466

  Torosyan, Y ^a   Dobi, A ^b   Glasman, M ^a   Mezhevaya, K ^a   Naga, S ^a   Huang, W ^a   Paweletz, C ^a   Leighton, X ^a   Pollard, H B ^a   Srivastava, M ^a  

^a Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^b Center for Prostate Disease Research   (United States)

Author keywords

Annexin A7; ANXA7 (or synexin); DNA affinity enrichment identification of nuclear proteins; Heterogeneous nuclear ribonucleoprotein; HnRNP; Mass spectrometry; Prostate cancer

Indexed keywords

HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; SYNEXIN;

ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; GENE DELETION; GENE MAPPING; HUMAN; HUMAN CELL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; RNA SPLICING; TRANSCRIPTION REGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANNEXIN A7; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP A-B; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN K; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEINS; HUMANS; MALE; PROMOTER REGIONS, GENETIC; PROSTATE; PROSTATIC NEOPLASMS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR SUPPRESSOR PROTEINS;

EID: 77951877471     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.2     Document Type: Article

References (51)

1. Adachi K, Tanaka T, Saito H, Oka T. (1999). Hormonal induction of mouse selenocysteine transfer ribonucleic acid (tRNA) gene transcription-activating factor and its functional importance in the selenocysteine tRNA gene transcription in mouse mammary gland. Endocrinology 140: 618-623.
2. Auboeuf D, Honig A, Berget SM, OMalley BW. (2002). Coordinate regulation of transcription and splicing by steroid receptor coregulators. Science 298: 416-419.
3. Barboro P, Repaci E, Rubagotti A, Salvi S, Boccardo S, Spina B et al. (2009). Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer. Br J Cancer 100: 1608-1616.
4. Burd CG, Swanson MS, Gorlach M, Dreyfuss G. (1989). Primary structures of the heterogeneous nuclear ribonucleoprotein A2, B1, and C2 proteins: a diversity of RNA binding proteins is generated by small peptide inserts. Proc Natl Acad Sci USA 86: 9788-9792.
5. Caron D, Winstall E, Inaguma Y, Michaud S, Lettre F, Bourassa S et al. (2008). Proteomic characterization of mouse cytosolic and membrane prostate fractions: high levels of free SUMO peptides are androgen-regulated. J Proteome Res 7: 4492-4499.
6. Carpenter B, MacKay C, Alnabulsi A, MacKay M, Telfer C, Melvin WT et al. (2006). The roles of heterogeneous nuclear ribonucleo-proteins in tumour development and progression. Biochim Biophys Acta 1765: 85-100.
7. Chen H, Stuart W, Hu B, Nguyen L, Huang G, Clemens TL et al. (2005). Creation of estrogen resistance in vivo by transgenic overexpression of the heterogeneous nuclear ribonucleoprotein-related estrogen response element binding protein. Endocrinology 146: 4266-4273.
8. Chen S, Wang J, Yu G, Liu W, Pearce D. (1997). Androgen and glucocorticoid receptor heterodimer formation. A possible mechanism for mutual inhibition of transcriptional activity. J Biol Chem 272: 14087-14092.
9. Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF. (2000). The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25- dihydroxyvitamin D2 as therapeutic agents for prostate cancer. Clin Cancer Res 6: 901-908.
10. Cooper TA, Wan L, Dreyfuss G. (2009). RNA and disease. Cell 136: 777-793.
11. Courchet J, Buchet-Poyau K, Potemski A, Bres A, Jariel-Encontre I, Billaud M. (2008). Interaction with 14-3-3 adaptors regulates the sorting of hMex-3B RNA-binding protein to distinct classes of RNA granules. J Biol Chem 283: 32131-32142.
12. Dobi A, Debnam W, Dalgard C, Owusu A, von Agoston D. (2002). Mammalian expression cloning of nucleic acid binding proteins by agarose thin-layer gelshift clone selection. Biotechniques 33: 868-872.
13. Duncan R, Carpenter B, Main LC, Telfer C, Murray GI. (2008). Characterisation and protein expression profiling of annexins in colorectal cancer. Br J Cancer 98: 426-433.
14. Eggert H, Schulz M, Fackelmayer FO, Renkawitz R, Eggert M. (2001). Effects of the heterogeneous nuclear ribonucleoprotein U (hnRNP U/SAF-A) on glucocorticoid-dependent transcription in vivo. J Steroid Biochem Mol Biol 78: 59-65.
15. Enge M, Bao W, Hedstrom E, Jackson SP, Moumen A, Selivanova G. (2009). MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell 15: 171-183.
16. Graveley BR. (2009). Alternative splicing: regulation without regulators. Nat Struct Mol Biol 16: 13-15.
17. He Y, Brown MA, Rothnagel JA, Saunders NA, Smith R. (2005). Roles of heterogeneous nuclear ribonucleoproteins A and B in cell proliferation. J Cell Sci 118: 3173-3183.
18. Heemers HV, Verhoeven G, Swinnen JV. (2006). Androgen activation of the sterol regulatory element-binding protein pathway: current insights. Mol Endocrinol 20: 2265-2277.
19. Hellwinkel OJ, Rogmann JP, Asong LE, Luebke AM, Eichelberg C, Ahyai S et al. (2008). A comprehensive analysis of transcript signatures of the phosphatidylinositol-3 kinase/protein kinase B signal-transduction pathway in prostate cancer. BJU Int 101: 1454-1460.
20. Hilbe W, Dirnhofer S, Greil R, Woll E. (2004). Biomarkers in non-small cell lung cancer prevention. Eur J Cancer Prev 13: 425-436.
21. Juven-Gershon T, Hsu JY, Theisen JW, Kadonaga JT. (2008). The RNA polymerase II core promoter\the gateway to transcription. Curr Opin Cell Biol 20: 253-259.
22. Kang HS, Angers M, Beak JY, Wu X, Gimble JM, Wada T et al. (2007). Gene expression profiling reveals a regulatory role for ROR alpha and ROR gamma in phase I and phase II metabolism. Physiol Genomics 31: 281-294.
23. Karagianni N, Tsawdaroglou N. (1994). The c-fos serum response element (SRE) confers negative response to glucocorticoids. Oncogene 9: 2327-2334.
24. Kim TH, Barrera LO, Zheng M, Qu C, Singer MA, Richmond TA et al. (2005). High-resolution map of active promoters in the human genome. Nature 436: 876-880. (Pubitemid 41160649)
25. Kimura E, Abe K, Suzuki K, Sorimachi H. (2003). Heterogeneous nuclear ribonucleoprotein K interacts with and is proteolyzed by calpain in vivo. Biosci Biotechnol Biochem 67: 1786-1796.
26. Lee BJ, Cansizoglu AE, Suel KE, Louis TH, Zhang Z, Chook YM. (2006). Rules for nuclear localization sequence recognition by karyopherin beta 2. Cell 126: 543-558.
27. Li T, Evdokimov E, Shen RF, Chao CC, Tekle E, Wang T et al. (2004). Sumoylation of heterogeneous nuclear ribonucleoproteins, zinc finger proteins, and nuclear pore complex proteins: a proteomic analysis. Proc Natl Acad Sci USA 101: 8551-8556.
28. Magendzo K, Shirvan A, Cultraro C, Srivastava M, Pollard HB, Burns AL. (1991). Alternative splicing of human synexin mRNA in brain, cardiac, and skeletal muscle alters the unique N-terminal domain. J Biol Chem 266: 3228-3232.
29. Mikula M, Dzwonek A, Karczmarski J, Rubel T, Dadlez M, Wyrwicz LS et al. (2006). Landscape of the hnRNP K protein-protein interactome. Proteomics 6: 2395-2406.
30. Mukhopadhyay NK, Kim J, Cinar B, Ramachandran A, Hager MH, Di Vizio D et al. (2009). Heterogeneous nuclear ribonucleoprotein K is a novel regulator of androgen receptor translation. Cancer Res 69: 2210-2218.
31. Myslinski E, Gerard MA, Krol A, Carbon P. (2006). A genome scale location analysis of human Staf/ZNF143-binding sites suggests a widespread role for human Staf/ZNF143 in mammalian promoters. J Biol Chem 281: 39953-39962.
32. Nakielny S, Dreyfuss G. (1999). Transport of proteins and RNAs in and out of the nucleus. Cell 99: 677-690.
33. Patry C, Bouchard L, Labrecque P, Gendron D, Lemieux B, Toutant J et al. (2003). Small interfering RNA-mediated reduction in heterogeneous nuclear ribonucleoparticule A1/A2 proteins induces apoptosis in human cancer cells but not in normal mortal cell lines. Cancer Res 63: 7679-7688.
34. Pollard HB, Caohuy H, Minton AP, Srivastava M. (1998). Synexin (annexin VII) hypothesis for Ca2+/GTP-regulated exocytosis. Adv Pharmacol 42: 81-87.
35. Reed R, Hurt E. (2002). A conserved mRNA export machinery coupled to pre-mRNA splicing. Cell 108: 523-531.
36. Rizzo G, Fiorucci S. (2006). PPARs and other nuclear receptors in inflammation. Curr Opin Pharmacol 6: 421-427.
37. Rozanov DV, Savinov AY, Williams R, Liu K, Golubkov VS, Krajewski S et al. (2008). Molecular signature of MT1-MMP: transactivation of the downstream universal gene network in cancer. Cancer Res 68: 4086-4096.
38. Sakaguchi M, Murata H, Sonegawa H, Sakaguchi Y, Futami J, Kitazoe M et al. (2007). Truncation of annexin A1 is a regulatory lever for linking epidermal growth factor signaling with cytosolic phospholipase A2 in normal and malignant squamous epithelial cells. J Biol Chem 282: 35679-35686.
39. Shi L, Ko S, Kim S, Echchgadda I, Oh TS, Song CS et al. (2008). Loss of androgen receptor in aging and oxidative stress through Myb protooncoprotein- regulated reciprocal chromatin dynamics of p53 and poly(ADP-ribose) polymerase PARP-1. J Biol Chem 283: 36474-36485.
40. Shi Y, Manley JL. (2007). A complex signaling pathway regulates SRp38 phosphorylation and pre-mRNA splicing in response to heat shock. Mol Cell 28: 79-90.
41. Shirvan A, Srivastava M, Wang MG, Cultraro C, Magendzo K, McBride OW et al. (1994). Divergent structure of the human synexin (annexin VII) gene and assignment to chromosome 10. Biochemistry 33: 6888-6901.
42. Srivastava M, Atwater I, Glasman M, Leighton X, Goping G, Caohuy H et al. (1999). Defects in inositol 1,4,5-trisphosphate receptor expression, Ca(2+) signaling, and insulin secretion in the anx7(+/\) knockout mouse. Proc Natl Acad Sci USA 96: 13783-13788.
43. Srivastava M, Montagna C, Leighton X, Glasman M, Naga S, Eidelman O et al. (2003). Haploinsufficiency of Anx7 tumor suppressor gene and consequent genomic instability promotes tumorigenesis in the Anx7(+/\) mouse. Proc Natl Acad Sci USA 100: 14287-14292.
44. Srivastava M, Pollard HB. (2000). Low in vivo levels of human anx7 (annexin VII) gene expression are due to endogenous inhibitory promoter sequences. Cell Biol Int 24: 475-481.
45. Srivastava M, Torosyan Y, Raffeld M, Eidelman O, Pollard HB, Bubendorf L. (2007). ANXA7 expression represents hormone-relevant tumor suppression in different cancers. Int J Cancer 121: 2628-2636.
46. Tokusumi Y, Ma Y, Song X, Jacobson RH, Takada S. (2007). The new core promoter element XCPE1 (X Core Promoter Element 1) directs activator-, mediator-, and TATA-binding protein-dependent but TFIID-independent RNA polymerase II transcription from TATA-less promoters. Mol Cell Biol 27: 1844-1858.
47. Torosyan Y, Dobi A, Naga S, Mezhevaya K, Glasman M, Norris C et al. (2006). Distinct effects of annexin A7 and p53 on arachidonate lipoxygenation in prostate cancer cells involve 5-lipoxygenase transcription. Cancer Res 66: 9609-9616.
48. Torosyan Y, Simakova O, Naga S, Mezhevaya K, Leighton X, Diaz J et al. (2009). Annexin-A7 protects normal prostate cells and induces distinct patterns of RB-associated cytotoxicity in androgen-sensitive and-resistant prostate cancer cells. Int J Cancer 125: 2528-2539.
49. Wolf M, Mousses S, Hautaniemi S, Karhu R, Huusko P, Allinen M et al. (2004). High-resolution analysis of gene copy number alterations in human prostate cancer using CGH on cDNA microarrays: impact of copy number on gene expression. Neoplasia 6: 240-247.
50. Yemelyanov A, Czwornog J, Chebotaev D, Karseladze A, Kulevitch E, Yang X et al. (2007). Tumor suppressor activity of glucocorticoid receptor in the prostate. Oncogene 26: 1885-1896. (Pubitemid 46474637)
51. Zheng Z, Cai C, Omwancha J, Chen SY, Baslan T, Shemshedini L. (2006). SUMO-3 enhances androgen receptor transcriptional activity through a sumoylation-independent mechanism in prostate cancer cells. J Biol Chem 281: 4002-4012.